Episode Details
Back to Episodes
Johnson and Johnson Stock Analysis: Strong Dividend Yield and Analyst Consensus in 2024
Published 1 month ago
Description
# Johnson & Johnson (JNJ) Stock Analysis: Strong Buy Signals, EU Drug Approval & Dividend Growth | March 2025 Market Update
Dive into the latest **Johnson & Johnson stock (JNJ)** analysis featuring the company's $579 billion market cap performance and recent positive catalysts. This episode covers:
✅ **Current Trading Data**: JNJ opened at $240.39 with a solid P/E ratio of 21.75 and low volatility (beta 0.34)
✅ **Major Catalyst**: European Medicines Agency approves expanded Darzalex administration for multiple myeloma patients
✅ **Analyst Upgrades**: Citigroup raises price target to $274 (Buy), RBC lifts to $255 (Outperform), plus updates from Barclays and JPMorgan
✅ **Consensus Rating**: Moderate Buy from 27 analysts with average target of $236.91
✅ **Dividend Income**: $5.20 annual payout yielding 2.2% - making JNJ a top dividend stock for 2026
✅ **Price Forecast**: CoinCodex projects potential rise to $248.72 within one month
Perfect for investors seeking **healthcare stocks**, **dividend aristocrats**, and **blue-chip investment opportunities**. Learn why analysts remain bullish on this pharmaceutical giant despite biosimilar competition risks.
*Subscribe for daily stock market analysis, earnings reports, and investment insights.*
**Keywords**: Johnson & Johnson stock, JNJ stock analysis, dividend stocks 2025, pharmaceutical stocks, healthcare investment, stock market news, analyst ratings, buy recommendations
---
*A Quiet Please Studios Production | Visit QuietPlease.ai for more financial podcasts*
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
This episode includes AI-generated content.
Dive into the latest **Johnson & Johnson stock (JNJ)** analysis featuring the company's $579 billion market cap performance and recent positive catalysts. This episode covers:
✅ **Current Trading Data**: JNJ opened at $240.39 with a solid P/E ratio of 21.75 and low volatility (beta 0.34)
✅ **Major Catalyst**: European Medicines Agency approves expanded Darzalex administration for multiple myeloma patients
✅ **Analyst Upgrades**: Citigroup raises price target to $274 (Buy), RBC lifts to $255 (Outperform), plus updates from Barclays and JPMorgan
✅ **Consensus Rating**: Moderate Buy from 27 analysts with average target of $236.91
✅ **Dividend Income**: $5.20 annual payout yielding 2.2% - making JNJ a top dividend stock for 2026
✅ **Price Forecast**: CoinCodex projects potential rise to $248.72 within one month
Perfect for investors seeking **healthcare stocks**, **dividend aristocrats**, and **blue-chip investment opportunities**. Learn why analysts remain bullish on this pharmaceutical giant despite biosimilar competition risks.
*Subscribe for daily stock market analysis, earnings reports, and investment insights.*
**Keywords**: Johnson & Johnson stock, JNJ stock analysis, dividend stocks 2025, pharmaceutical stocks, healthcare investment, stock market news, analyst ratings, buy recommendations
---
*A Quiet Please Studios Production | Visit QuietPlease.ai for more financial podcasts*
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
This episode includes AI-generated content.